Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neurosurgery ; 94(1): 165-173, 2024 01 01.
Artigo em Inglês | MEDLINE | ID: mdl-37523519

RESUMO

BACKGROUND AND OBJECTIVES: An international, multicenter, retrospective study was conducted to evaluate the long-term clinical outcomes and tumor control rates after stereotactic radiosurgery (SRS) for trigeminal schwannoma. METHODS: Patient data (N = 309) were collected from 14 international radiosurgery centers. The median patient age was 50 years (range 11-87 years). Sixty patients (19%) had prior resections. Abnormal facial sensation was the commonest complaint (49%). The anatomic locations were root (N = 40), ganglion (N = 141), or dumbbell type (N = 128). The median tumor volume was 4 cc (range, 0.2-30.1 cc), and median margin dose was 13 Gy (range, 10-20 Gy). Factors associated with tumor control, symptom improvement, and adverse radiation events were assessed. RESULTS: The median and mean time to last follow-up was 49 and 65 months (range 6-242 months). Greater than 5-year follow-up was available for 139 patients (45%), and 50 patients (16%) had longer than 10-year follow-up. The overall tumor control rate was 94.5%. Tumors regressed in 146 patients (47.2%), remained unchanged in 128 patients (41.4%), and stabilized after initial expansion in 20 patients (6.5%). Progression-free survival rates at 3 years, 5 years, and 10 years were 91%, 86%, and 80 %. Smaller tumor volume (less than 8 cc) was associated with significantly better progression-free survival ( P = .02). Seventeen patients with sustained growth underwent further intervention at a median of 27 months (3-144 months). Symptom improvement was noted in 140 patients (45%) at a median of 7 months. In multivariate analysis primary, SRS ( P = .003) and smaller tumor volume ( P = .01) were associated with better symptom improvement. Adverse radiation events were documented in 29 patients (9%). CONCLUSION: SRS was associated with long-term freedom (10 year) from additional management in 80% of patients. SRS proved to be a valuable salvage option after resection. When used as a primary management for smaller volume tumors, both clinical improvement and prevention of new deficits were optimized.


Assuntos
Neoplasias dos Nervos Cranianos , Neurilemoma , Radiocirurgia , Humanos , Criança , Adolescente , Adulto Jovem , Adulto , Pessoa de Meia-Idade , Idoso , Idoso de 80 Anos ou mais , Estudos de Coortes , Radiocirurgia/métodos , Estudos Retrospectivos , Neurilemoma/diagnóstico por imagem , Neurilemoma/radioterapia , Neurilemoma/cirurgia , Intervalo Livre de Progressão , Neoplasias dos Nervos Cranianos/cirurgia , Resultado do Tratamento , Seguimentos
2.
Neurosurg Rev ; 45(1): 525-531, 2022 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-33977410

RESUMO

We present our experience with Gamma Knife surgery (GKS) and refractory glossopharyngeal neuralgia (GPN), analyzing its usefulness and safety in patients with or without previous surgeries, another concomitant neuralgia, or retreats. In addition, we study some factors that could condition the outcome of this technique. According to our review, our follow-up is the longest in the literature. We performed the prospective study of 8 patients submitted to GKS between 2008 and 2020. We employed the Leksell radiosurgery Gamma Knife system. The cases were evaluated before and after surgery (3, 6, 12 months and then annually). The VAS (Visual Analogue Scale) and BNI (Barrow Neurological Institute) scale were used. The data were assessed with SPSS25. Our series was composed of 6 (75%) women and 2 (25%) men, with an average age of 59.5 ± 14.04 years. Six patients (75%) had one or more than one previous surgeries. The median follow-up time was 7.22 ± 3.66 years (1.08-12.5 years). In the short-term postoperative period (1 year), eight patients (100%) experienced significant pain relief (VAS, p = 0.012; BNI I-IIIb). After the last interview, 5 patients felt pain relief (62.5%) (BNI grade I = 3; BNI grade IIIa = 2); 3 patients (37.5%) (BNI grade IV) were retreated (MVD, 2; GKS, 1). We found no association between patients with long evolution time of disease (p = 0.356), previous surgeries (p = 0.206), or vascular contact (p = 0.673) and worse clinical results after GKS. Both morbidity and mortality were 0%. Our results suggest that GKS for treating drug-resistant GPN with high initial doses is both a minimally invasive and useful and effective therapeutic strategy, without permanent complications. It presents good results even in patients with one or more previous surgical interventions. These findings encourage us to use this non-invasive technique as initial therapy against the invasive options.


Assuntos
Doenças do Nervo Glossofaríngeo , Radiocirurgia , Neuralgia do Trigêmeo , Idoso , Feminino , Seguimentos , Doenças do Nervo Glossofaríngeo/cirurgia , Humanos , Masculino , Pessoa de Meia-Idade , Estudos Prospectivos , Resultado do Tratamento , Neuralgia do Trigêmeo/cirurgia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...